JP2014515366A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515366A5
JP2014515366A5 JP2014511894A JP2014511894A JP2014515366A5 JP 2014515366 A5 JP2014515366 A5 JP 2014515366A5 JP 2014511894 A JP2014511894 A JP 2014511894A JP 2014511894 A JP2014511894 A JP 2014511894A JP 2014515366 A5 JP2014515366 A5 JP 2014515366A5
Authority
JP
Japan
Prior art keywords
composition according
active ingredient
carbon atoms
composition
nail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511894A
Other languages
English (en)
Other versions
JP6023181B2 (ja
JP2014515366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/059788 external-priority patent/WO2012160180A2/en
Publication of JP2014515366A publication Critical patent/JP2014515366A/ja
Publication of JP2014515366A5 publication Critical patent/JP2014515366A5/ja
Application granted granted Critical
Publication of JP6023181B2 publication Critical patent/JP6023181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)

  1. 有効量の活性成分と、式
    RFRH
    または
    RFRHRF
    に係る部分フッ素化アルカンと、を含む爪を侵す疾患または状態の予防または処置に使用される局所医薬組成物であって、
    式中、RFは、20個以下の炭素原子を有する過フッ素化炭化水素セグメントであり、RHは、3〜20個の炭素原子を有する非フッ素化炭化水素セグメントであり、
    爪に投与される、局所医薬組成物。
  2. 部分フッ素化アルカンが、式
    RFRH
    で示される化合物であり、
    式中、RFは、4〜12個の炭素原子を有する直鎖状過フッ素化セグメントであり、RHは、4〜8個の炭素原子を有する直鎖状アルキル基である、請求項1に記載の組成物。
  3. 部分フッ素化アルカンが、F4H5、F4H6、F4H8、F6H6およびF6H8から選択される、請求項2に記載の組成物。
  4. 液体もしくは半固形溶液、ゲル、スプレー、エマルジョン、懸濁液、マイクロエマルジョン、ネイルラッカー、または貼付薬の形態である、請求項1〜3のいずれか1項に記載の組成物。
  5. エタノール、アセトン、酢酸エチル、イソプロピルアルコール、グリセロール、プロピレングリコール、ペンチレングリコール、ポリエチレングリコール、液状パラフィン、トリグリセリド油、ヒドロフルオロカーボン、例えばHFA 134aおよび/またはHFA 227、ならびに液体モノまたはジグリセリドから選択される、生理学的に許容し得る共溶媒を含む、請求項1〜4のいずれか1項に記載の組成物。
  6. 前記爪を侵す疾患が爪乾癬である、請求項1〜5のいずれか1項に記載の組成物。
  7. 活性成分が、タクロリムス、シロリムス、エベロリムス、ピメクロリムス、リダフォロリムス、テムシロリムス、ゾタロリウムス、およびシクロスポリンAなどのマクロライド系免疫抑制剤から選択される、請求項6に記載の組成物。
  8. 活性成分が、レチノール、レチナール、トレチノイン、イソトレチノイン、アリトレチノイン、エトレチナート、アシトレチン、タザロテン、ベキサロテンおよびアダパレンなどのレチノイドから選択される、請求項6に記載の組成物。
  9. 活性成分が、カルシポトリオール、カルシトリオール、またはタカルシトールなどのビタミンD類似体から選択される、請求項6に記載の組成物。
  10. 前記爪を侵す疾患が爪真菌症である、請求項1〜5に記載の組成物。
  11. 活性成分が、クロトリマゾール、ケトコナゾール、またはミコナゾールなどのアゾール系;あるいはテルビナフィン、ナフチフィン、またはブテナフィンなどのアリルアミン系;あるいはシクロピロキソラミン、またはアモロルフィンなどの他の抗真菌薬から選択される、請求項10に記載の組成物。
  12. 活性成分が、抗生物質、コルチコステロイド、非ステロイド系抗炎症薬、局所麻酔薬、または5−フルオロウラシルから選択される、請求項1〜5に記載の組成物。
JP2014511894A 2011-05-25 2012-05-24 爪に投与するための医薬組成物 Active JP6023181B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11167552 2011-05-25
EP11167552.6 2011-05-25
EP11167732.4 2011-05-26
EP11167732 2011-05-26
EP11174545 2011-07-19
EP11174545.1 2011-07-19
PCT/EP2012/059788 WO2012160180A2 (en) 2011-05-25 2012-05-24 Pharmaceutical composition for administration to nails

Publications (3)

Publication Number Publication Date
JP2014515366A JP2014515366A (ja) 2014-06-30
JP2014515366A5 true JP2014515366A5 (ja) 2015-07-09
JP6023181B2 JP6023181B2 (ja) 2016-11-09

Family

ID=46172789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511894A Active JP6023181B2 (ja) 2011-05-25 2012-05-24 爪に投与するための医薬組成物

Country Status (10)

Country Link
US (1) US9308262B2 (ja)
EP (1) EP2714008B1 (ja)
JP (1) JP6023181B2 (ja)
KR (1) KR101773648B1 (ja)
CN (1) CN103561724B (ja)
AU (1) AU2012260788B2 (ja)
CA (1) CA2834862C (ja)
DK (1) DK2714008T3 (ja)
ES (1) ES2617968T3 (ja)
WO (1) WO2012160180A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012160179A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
KR102171897B1 (ko) 2012-09-12 2020-11-02 노바리크 게엠베하 부분불소화 알칸 조성물
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
EP3024484B1 (en) 2013-07-23 2018-06-20 Novaliq GmbH Stabilized antibody compositions
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ,インコーポレイテッド 化合物および爪光沢剤
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
KR102351816B1 (ko) 2017-04-21 2022-01-17 노바리크 게엠베하 요오드 조성물
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN111991404B (zh) * 2020-10-10 2021-08-13 西南医科大学 防治真菌感染的复合维生素d及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022A (en) 1853-09-13 Lard-lamp
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
IN184589B (ja) 1996-10-16 2000-09-09 Alza Corp
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
CA2361424C (en) 1999-02-08 2009-04-28 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
DE60223694T2 (de) * 2001-09-04 2008-10-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
CA2563544A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
US20050288196A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer contact lens compositions and methods of use
NZ552481A (en) 2004-07-01 2008-12-24 Schepens Eye Res Compositions and methods for treating eye disorders and conditions
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
BRPI0614084A2 (pt) 2005-08-05 2011-03-09 Bharat Serums & Vaccines Ltd composição estável de emulsão de óleo-em-água de propofol, administrável por via intranovesa; e processo de preparação de uma composição
FR2892023B1 (fr) * 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス,インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010150378A1 (ja) 2009-06-25 2010-12-29 ライオン株式会社 眼科用組成物
CA2752849C (en) * 2009-07-24 2014-07-08 Bernd G. Seigfried Liquid compositions capable of foaming and including active agents, and methods for making or developing same
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2819988C (en) 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
WO2012160179A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
KR102171897B1 (ko) 2012-09-12 2020-11-02 노바리크 게엠베하 부분불소화 알칸 조성물
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物

Similar Documents

Publication Publication Date Title
JP2014515366A5 (ja)
JP2014517841A5 (ja)
ES2623233T3 (es) Composición farmacéutica tópica a base de alcanos semifluorados
JP6023181B2 (ja) 爪に投与するための医薬組成物
US10363314B2 (en) Sprayable topical carrier and composition comprising phosphatidylcholine
JP2015531344A5 (ja)
JP2018526325A5 (ja)
JP2012131827A5 (ja)
HRP20150154T1 (hr) Raspršivi farmaceutski pripravak koji sadrži analog vitamina d i kortikosteroid
JP2016500095A5 (ja)
JP2013100317A5 (ja)
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
WO2011134944A3 (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
JP2015527386A5 (ja)
JP2012524771A5 (ja)
JP2016515530A5 (ja)
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
RU2018103940A (ru) Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза
JP2014509655A5 (ja)
TW200911301A (en) Pharmaceutical composition for topical application of poorly soluble compounds
JP2009523750A5 (ja)
US20160256474A1 (en) Topical spray composition of halobetasol
AR089666A1 (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico
RU2016121390A (ru) Фармацевтические, косметические и дезинфицирующие композиции для местного применения, содержащие фосфатидилхолин